1-Benzo[b]thien-4-ylpiperazine monohydrochloride

We are 1-Benzo[b]thien-4-ylpiperazine monohydrochloride CAS:913614-18-3 manufacturer and supplier in China, Pls send inquiry of to info@nbinno.com of visit www.nbinno.com our official website should you have any interests

Chemical Name: 1-Benzo[b]thien-4-ylpiperazine monohydrochloride
CAS.NO:  913614-18-3
Synonyms:
1-(1-Benzothiophen-4-yl)piperazine hydrochloride (1:1)
Piperazine, 1-benzo[b]thien-4-yl-, hydrochloride (1:1)
PIPERAZINE, 1-BENZO[B]THIEN-4-YL,HYDROCLORIDE
1-Benzo[b]thien-4-ylpiperazine monohydrochloride

Molecular Formula: C12H15ClN2S
Molecular Weight:   254.77900

Physical and Chemical Properties:

Specification:
Appearance: White Powder
Purity:≥99.0%
Loss on drying:≤0.5%
Heavy metals:≤10 ppm
Water:≤1.0%
Inorganic salt:≤0.1%
Non-specific impurity:≤0.10%
Total Impurities:≤0.50%

Packing:
 25kg  cardboard drum or according to customer specified requirements
Storage:Stored in a cool and dry well-closed container. Keep away from moisture and strong light/heat.
Application:Intermediates of Brexpiprazole CAS:913611-97-9

Related News: The clinical trial International Study of Phase 3 IV RigosErtib, or INSPIRE, was finalized following guidance received from the U.S. Food and Drug Administration and European Medicines Agency.D-Asparagine Monohydrate The clinical trial International Study of Phase 3 IV RigosErtib, or INSPIRE, was finalized following guidance received from the U.S. Food and Drug Administration and European Medicines Agency.N6- (2-metiltioetil) -2- (3,3,3-trifluoropropiltio) adenosina CAS:163706-58-9 DMF is the main management method for APIs in developed countries in Europe and the United States. Under the DMF system, API companies can submit DMF filing documents to the regulatory authority at any time, but the regulatory authority will not conduct technical reviews on them. When the drug is administered, the regulatory authority will associate and review the drug substance and the preparation.Glycine Only when the drug substance is processed into a pharmaceutical preparation can it become a drug for clinical application.Only when the drug substance is processed into a pharmaceutical preparation can it become a drug for clinical application.